• / Free eNewsletters & Magazine
  • / My Account
Home>Finance>Securities Litigation Reform Act

Securities Litigation Reform Act

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Becker Professional Education Announces Closing of ACAMS Acquisition

    Becker Professional Education Announces Closing of ACAMS Acquisition

  2. KCP&L Files Rate Increase Request with Missouri Public Service Commission

    KCP&L Files Rate Increase Request with Missouri Public Service Commission

  3. Assured Guaranty Corp. Completes Acquisition of CIFG Assurance North America, Inc.

    Assured Guaranty Corp. Completes Acquisition of CIFG Assurance North America, Inc.

  4. Buenaventura Announces the Completion of Its Debt Reprofiling

    Buenaventura Announces the Completion of Its Debt Reprofiling

  5. Hines REIT Announces Liquidation Plan

    Hines REIT Announces Liquidation Plan

  6. CorPath System to Be Featured for Complex Interventions At SDCI 2016: San Diego Cardiovascular Interventions Course

    CorPath System to Be Featured for Complex Interventions At SDCI 2016: San Diego Cardiovascular Interventions Course

  7. Leap Therapeutics Presents Positive Data from Clinical Study of DKN-01 in Combination with Paclitaxel in Esophageal Cancer

    Leap Therapeutics Presents Positive Data from Clinical Study of DKN-01 in Combination with Paclitaxel in Esophageal Cancer

  8. Delta Galil to Acquire Contemporary Premium Brands from VF Corp

    Delta Galil to Acquire Contemporary Premium Brands from VF Corp

  9. Autoliv is Cooperating with Toyota in a Voluntary Recall of Certain Prius and Lexus CT Vehicles

    Autoliv is Cooperating with Toyota in a Voluntary Recall of Certain Prius and Lexus CT Vehicles

  10. Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA® (pembrolizumab) for the Treatment of Multiple Types of Cancer

    Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA® (pembrolizumab) for the Treatment of Multiple Types of Cancer

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.